Citations

Clear

789 citation(s) found for "Jenkins, RB".

Glioblastoma, IDH-Wildtype Harboring a KIAA1549::BRAF Fusion: Report of a Case With Comprehensive Molecular Profiling
Berry, John F. , Vidrine, Devan W. , Wojcik, Antonina A, Trivedi, Darshan, Quezado, Martha , Abdullaev, Zied , Ketchum, Courtney , Aldape, Kenneth , Jenkins, Robert B. , Aldape, Kenneth , Jenkins, Robert, Ida, Cristiane M , Wojcik, Antonina A., Keen, Joseph, Pratt, Drew , Ida, Cristiane M.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | August 27, 2022 | Volume: 81 | Issue: 12 | Pages: 1026-1028

10.1093/jnen/nlac076 | PMID 36029520 Get It

Pleomorphic Liposarcoma
Gjeorgjievski, Sandra Gjorgova , Thway, Khin , Fisher, Cyril , Jenkins, Sarah M. , Thangaiah, Judith Jebastin, Folpe, Andrew L. , Fritchie, Karen , Gjorgova Gjeorgjievski, Sandra , Thangaiah, Judith J., Dermawan, Josephine K. , John, Ivy , Rubin, Brian P.

Mayo Clinic

American Journal of Surgical Pathology | August 25, 2022 | Volume: 46 | Issue: 12 | Pages: 1700-1705

10.1097/pas.0000000000001962 | PMID 36006773 Get It

Pleomorphic liposarcoma (PLPS) is a highly aggressive sarcoma comprising variable numbers of pleomorphic lipoblasts mixed with undifferentiated pleomorphic sarcoma (UPS)-like areas. Morphologic variants, such as myxofibrosarcoma-like or epithelioid, may cause diagnostic confusion, especially on a core biopsy, but there are few data on the prognostic significance of these features. A total of 120 PLPS biopsies and resection specimens were reviewed and catalogued based on the presence of myxofibrosarcoma-like, UPS-like, and epithelioid foci, in 10% increments. The clinical parameters were collected. Cases occurred in 75 males and 45 females, ranging from 8 to 98 years (median, 62.5 y). Cases arose in the extremities (n=72), trunk (n=32), head/neck (n=10), bone (n=4), mediastinum (n=1), or viscera (colon polyp, n=1). Of those with known depth (n=81), 40 were intramuscular, 34 were subcutaneous, and 7 arose in the dermis. Their sizes ranged from 1 to 24.5 cm (median, 7 cm). Of the patients with ≥1 month of follow-up (n=70), 5 had recurrence and 15 had metastasis. The 5-year overall survival and event-free survival rates were 66.2% and 63.1%, respectively. Tumors ≥5 cm had inferior overall survival compared with tumors <5 cm. The presence of epithelioid areas was also statistically significant in terms of poorer overall survival and event-free survival, while tumors with ≥50% undifferentiated pleomorphic-like areas had better overall survival. There was a trend towards poorer outcomes in tumors with necrosis (≥1%). PLPS is an aggressive adipocytic malignancy that is most commonly present in the extremities of older adults. The morphologic features of these tumors are diverse, and they may be mistaken for UPS or myxofibrosarcoma, carcinoma, and melanomas, particularly on biopsies. Tumor size, necrosis, and epithelioid morphology are associated with adverse prognosis.
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions
Miller, Julie J. , Castro, L. Nicolas Gonzalez , McBrayer, Samuel K. , Weller, Michael , Andronesi, Ovidiu C. , Baumert, Brigitta G. , Berger, Mitchel S. , Chang, Susan M. , Costello, J , Huang, Raymond Y. , Jenkins, Robert B. , Mellinghoff, Ingo K. , Platten, Michael , Reardon, David A. , Schiff, David , Yan, Hai , Bent, Martin J. van den , Kaelin, William G. , Wen, Patrick Y. , Gonzalez Castro, L Nicolas , Berger, Mitchell S , Bindra, Ranjit , Cahill, Daniel P. , Horbinski, Craig , Jenkins, RB , Wick, Wolfgang , Weller, Michael , van den Bent, Martin J , Platten, Michael , Mellinghoff, Ingo K , Huang, Raymond , Cloughesy, Timothy F. , Portnow, Jana , Barnholtz‐Sloan, Jill S. , Bi, Wenya Linda , Bindra, Ranjit S. , Horbinski, Craig , Ligon, Keith L , Nabors, Burt , Shi, Diana D. , Wick, Wolfgang , Deimling, Andreas von , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | August 24, 2022 | Volume: 25 | Issue: 1 | Pages: 4-25

10.1093/neuonc/noac207 | PMID 36239925 Get It

Abstract Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant primary brain tumors diagnosed in patients younger than 50, constituting an important cause of morbidity and mortality. In recent years, there has been significant progress in understanding the molecular pathogenesis and biology of these tumors, sparking multiple efforts to improve their diagnosis and treatment. In this consensus review from the Society for Neuro-Oncology (SNO), the current diagnosis and management of IDH-mutant gliomas will be discussed. In addition, novel therapies, such as targeted molecular therapies and immunotherapies, will be reviewed. Current challenges and future directions for research will be discussed.
Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma
Ensign, Shannon P. Fortin , Jenkins, Robert B. , Giannini, Caterina , Sarkaria, Jann N. , Galanis, Evanthia , Kizilbash, Sani H. , Fortin Ensign, Shannon P, Ensign, Shannon P. Fortin , Galanis, Evanthia , Giannini, Caterina , Sarkaria, Jann N , Kizilbash, Sani H

Mayo Clinic

Neuro-Oncology | August 17, 2022 | Volume: 25 | Issue: 1 | Pages: 28-36

10.1093/neuonc/noac205 | PMID 35973817 Get It

Abstract Isocitrate dehydrogenase (IDH) 1 or 2 mutations confer a favorable prognosis compared to IDH-wildtype in astrocytoma, frequently denoting a lower grade malignancy. However, recent molecular profiling has identified specific aggressive tumor subgroups with clear clinical prognostic implications that are independent of histologic grading. The homozygous deletion of CDKN2A/B is the strongest implicated independent indicator of the poor prognosis within IDH-mutant astrocytoma, and the identification of this alteration in these lower histologic grade tumors transforms their biology toward an aggressive grade 4 phenotype clinically. CDKN2A/B homozygous deletion is now sufficient to define a grade 4 tumor in IDH-mutant astrocytomas regardless of histologic appearance, yet there are currently no effective molecularly informed targeted therapies for these tumors. The biological impact of CDKN2A/B homozygous deletion in IDH-mutant tumors and the optimal treatment strategy for this molecular subgroup remains insufficiently explored. Here we review the current understanding of the translational significance of homozygous deletion of CDKN2A/B gene expression in IDH-mutant astrocytoma and associated diagnostic and therapeutic implications.
Polygenic risk score analysis identifies deleterious protein-coding variants in novel immune pathway genes ATP8B4, FCGR1A, and LILRB1 that associate with Alzheimer’s disease.
Reddy, Joseph S. , Wang, Xue , Allen, Mariet , Carrasquillo, Minerva M. , Jenkins, Gregory D. , Belbin, Olivia , Golde, Todd E. , Ertekin‐Taner, Nilüfer , Younkin, Steven G. , Belbin, Olivia , Carrasquillo, Minerva M. , Biernacka, Joanna M. , Coombes, Brandon J.

Mayo Clinic

No container title available | August 3, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1885551/v1 Get It

Abstract Background: Alterations in innate immunity are pathologically associated with and genetically implicated in Alzheimer’s disease (AD). In the whole exome sequence (WES) dataset generated by the Alzheimer’s Disease Sequencing Project (ADSP), only the previously identified p.R47H variant in the innate immunity gene, TREM2, shows study-wide association with risk of AD. Using a novel approach, we searched the ADSP WES data to identify additional immune pathway genes with deleterious variants that, like TREM2.pR47H, show strong association with AD. Methods: Using polygenic risk scores (PRS) to analyze association with AD, we evaluated deleterious variants (CADD Phred-scaled score > 20) with a minor allele count of 20 or more in 228 genes comprising an immune co-expression network containing TREM2 (CENTREM2). A significant polygenic component composed of deleterious stop-gain and non-synonymous variants was identified, and false discovery rates were determined for the variants in this component. In genes harboring a significant variant, PRS for all variants in the genes were then analyzed. Results: The PRS for the 182 deleterious variants in CENTREM2 showed significant association with AD that was driven by 142 deleterious variants (136 non-synonymous, 6 stop-gain). In the 142 variant polygenic component, four variants had significant AD risk association: TREM2.pR47H, two deleterious stop-gain variants (FCGR1A.pR92X, and LILRB1.pY331X) in novel AD genes and 1 non-synonymous variant (ATP8B4.pG395S). Remarkably, PRS for the 36 additional variants in these four genes also showed significant association with AD. The PRS for all 40 variants in the 4 genes, showed significant, replicable association with AD and 3 additional variants in this polygenic component had significant false discovery rates: ATP8B4.pR1059Q, LILRB1.pP7P, and LILRB1.pY327Y. Conclusions: Here, we identify 3 immune pathway genes (ATP8B4, LILRB1, and FCGR1A) with a variant that associates with AD. Like TREM2.pR47H, each of the variants has a minor allele frequency less than 1% and is a deleterious, protein altering variant with a strong effect that increases or decreases (LILRB1.pY331X) risk of AD. Additional variants in these genes also alter risk of AD. The variants identified here are ideally suited for studies aimed at understanding how the innate immune system may be modulated to alter risk of AD.
Comprehensive Diabetes Autoantibody Laboratory-Based Clinical Service Testing in 6044 Consecutive Patients: Analysis of Age and Sex Effects
Dahl, Amanda , Jenkins, Sarah M. , Pittock, Sean J. , Mills, John R. , Foster, Jesica, Pittock, Siobhán T. , Pittock, Siobhan , Pittock, S J , McKeon, Andrew

Mayo Clinic

The Journal of Applied Laboratory Medicine | July 28, 2022 | Volume: 7 | Issue: 5 | Pages: 1037-1046

10.1093/jalm/jfac037 | PMID 35899533 Get It

Abstract Background In 2017, Mayo Clinic Laboratories commenced offering a comprehensive type 1 diabetes mellitus (T1DM) autoantibody (Ab) evaluation including 4 known Abs targeting glutamic acid decarboxylase (GAD65), protein tyrosine phosphatase-like islet antigen 2 (IA2), insulin (IAA), and zinc transporter 8 protein (ZnT8) antigens. Methods The objective of this study was to evaluate real-time data on the frequency and patterns of all 4 Abs stratified by age and sex from 6044 unique consecutive adult and pediatric patients undergoing evaluation for suspected diabetes. Results At least one Ab was found in 3370 (56%) of all samples: 67% of children (aged 0–17), 49% of young adults (aged 18–35), and 41% for both middle-aged (aged 36–55) and older (aged &gt;55) adults (P ≤ 0.0001). GAD65-Abs were the most common in all age groups, followed by ZnT8-Ab in those &lt;36 years, or IAA-Ab in those ≥36. Frequencies of IA2- and ZnT8-Abs drop significantly with increasing age. Clusters of 3 or 4 Abs were more frequently encountered in younger patients (41% of children vs 12% in middle- and 13% in older age groups, P ≤ 0.0001). Conclusions Children undergoing serological evaluation for T1DM were more commonly positive for autoantibodies than older age groups. The frequency of ZnT8- and IA2-Abs decreases, and IAA-Ab frequency increases with increasing age, and clusters of 2 to 4 autoantibodies are more common in children. In clinical practice, comprehensive testing for diabetes autoantibodies resulted in a switch in diagnosis to T1DM for patients previously classified as type 2 diabetes mellitus.
ASHP Statement on Telehealth Pharmacy Practice
Begnoche, Brendan R, Butler, Charlotte, Carson, Paige H, Darr, Andrea, Jenkins, Matthew T. , McDaniel, Robert B, Mourad, Hesham , Shipman, Colleen J., Stratton, Timothy P., Tran, Kelvin , Butler, C David, Jenkins, Matthew T, Le, Trinh , Tran, Kelvin, Wong, Kong (Kit)

Mayo Clinic

American Journal of Health-System Pharmacy | July 22, 2022 | Volume: 79 | Issue: 19 | Pages: 1728-1735

10.1093/ajhp/zxac188 | PMID 35866463 Get It

Community-Based, Cluster-Randomized Pilot Trial of a Cardiovascular Mobile Health Intervention: Preliminary Findings of the FAITH! Trial
Brewer, LaPrincess C. , Jenkins, Sarah M. , Hayes, Sharonne N. , Kumbamu, Ashok , Patten, Christi A. , Hayes, Sharonne N , Brewer, LaPrincess C , Jones, Clarence , Burke, Lora E. , Cooper, Lisa A.

Mayo Clinic

Circulation | July 18, 2022 | Volume: 146 | Issue: 3 | Pages: 175-190

10.1161/circulationaha.122.059046 | PMID 35861762 Get It

Background: African Americans continue to have suboptimal cardiovascular health (CVH) based on the American Heart Association Life’s Simple 7 (LS7), 7 health-promoting behaviors and biological risk factors (eg, physical activity, blood pressure). Innovative, community-level interventions in partnership with trusted institutions such as African American churches are potential means to improve CVH in this population. Methods: Using a community-based participatory research approach, the FAITH! Trial (Fostering African American Improvement in Total Health) rigorously assessed the feasibility and preliminary efficacy of a refined, community-informed, mobile health intervention (FAITH! App) for promoting CVH among African Americans in faith communities using a cluster randomized controlled trial. Participants from 16 churches in Rochester and Minneapolis-St Paul, MN, were randomized to receive the FAITH! App (immediate intervention) or were assigned to a delayed intervention comparator group. The 10-week intervention core features included culturally relevant and LS7-focused education modules, diet/physical activity self-monitoring, and a group sharing board. Data were collected via electronic surveys and health assessments. Primary outcomes were average change in mean LS7 score (continuous measure of CVH ranging from poor to ideal [0–14 points]) from baseline to 6 months post-intervention (using generalized estimating equations) and app engagement/usability (by the Health Information Technology Usability Evaluation Scale; range, 0–5). Results: Of 85 enrolled participants (randomized to immediate [N=41] and delayed [control] intervention [N=44] groups), 76 and 68 completed surveys/health assessments at baseline and 6 months post-intervention, respectively (80% retention rate with assessments at both baseline and 6-month time points); immediate intervention [N=30] and control [N=38] groups). At baseline, the majority of participants (mean age [SD], 54.2 [12.3] years, 71% female) had <4-year college education level (39/66, 59%) and poor CVH (44% in poor category; mean LS7 score [SD], 6.8 [1.9]). The mean LS7 score of the intervention group increased by 1.9 (SD 1.9) points compared with 0.7 (SD 1.7) point in the control group (both P <0.0001) at 6 months. The estimated difference of this increase between the groups was 1.1 (95% CI, 0.6–1.7; P <0.0001). App engagement/usability was overall high (100% connection to app; >75% completed weekly diet/physical activity tracking; Health Information Technology Usability Evaluation Scale, mean [SD], 4.2 [0.7]). Conclusions: On the basis of preliminary findings, the refined FAITH! App appears to be an efficacious mobile health tool to promote ideal CVH among African Americans. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03777709.
Sign of the times: Community engagement to refine a cardiovascular mHealth intervention through a virtual focus group series during the COVID-19 Pandemic
Brewer, LaPrincess C. , Cyriac, Jissy , Kumbamu, Ashok , Jenkins, Sarah M. , Hayes, Sharonne N. , Hayes, Sharonne N , Patten, Christi A. , Brewer, LaPrincess C , Burke, Lora E. , Jones, Clarence , Cooper, Lisa A.

Mayo Clinic

DIGITAL HEALTH | July 18, 2022 | Volume: 8 | Issue: No issue available | Pages: 205520762211105

10.1177/20552076221110537 | PMID 35874864 Get It

Background African-Americans are underrepresented in mobile health intervention research studies which can perpetuate health inequities and the digital divide. A community-based, user-centered approach to designing mobile health interventions may increase their sociocultural relevance and effectiveness, especially with increased smartphone use during the coronavirus disease 2019 pandemic. We aimed to refine an existing mobile health intervention via a virtual focus group series. Methods African-American community members (n = 15) from churches in Minneapolis-St. Paul and Rochester, Minnesota were enrolled in a virtual (via videoconferencing), three-session focus group series over five months to refine a cardiovascular health-focused mobile health application (FAITH! [Fostering African-American Improvement in Total Health!] App). Participants accessed the app via their smartphones and received a Fitbit synced to the app. Participants engaged with multimedia cardiovascular health-focused education modules, a sharing board for social networking, and diet/physical activity self-monitoring. Participant feedback on app features prompted iterative revisions to the FAITH! App. Primary outcomes were app usability (assessed via Health Information Technology Usability Evaluation Scale range: 0–5) and user satisfaction. Results Participants (mean age [SD]: 56.9 [12.3] years, 86.7% female) attended a mean 2.8 focus groups (80% attended all sessions). The revised FAITH! App exceeded the goal Health Information Technology Usability Evaluation Scale score threshold of ≥4 (mean: 4.39, range: 3.20–4.95). Participants positively rated updated app content, visual appeal, and use of social incentives to maintain engagement. Increasing user control and refinement of the moderated sharing board were identified as areas for future improvement. Conclusions Community-partnered, virtual focus groups can optimize usability and increase participant satisfaction of mobile health lifestyle interventions that aim to promote cardiovascular health in African-Americans.
The 100 Most-Cited and Influential Articles in Collegiate Athletics
Jenkins, Anna , Makovicka, Justin L. , Brinkman, Joseph C. , Jenkins, Anna S, Jenkins, Anna S , Pollock, Jordan Riley , Moore, M. Lane , Chhabra, Anikar

Mayo Clinic

Orthopaedic Journal of Sports Medicine | July 8, 2022 | Volume: 10 | Issue: 7 | Pages: No page available

10.1177/23259671221108401 | PMID 35837444 Get It

Background: Bibliometric citation analyses have been widely used in medicine to help researchers gain foundational knowledge about a topic and identify subtopics of popular interest for further investigations. There is a lack of similar research in collegiate athletics. Purpose: To identify the 100 most-cited research publications related to collegiate athletics. Study Design: Cross-sectional study. Methods: The Clarivate Analytics Web of Knowledge database was used to generate a list of articles relating to collegiate athletics on January 24, 2022. Articles were filtered by the total number of citations, and the 100 most-cited articles were selected. For each article, we identified and analyzed the following: author name, publication year, country of origin, journal name, article type, main research topic area, competitive level, sex of study population, and level of evidence. Results: Of the top 100 most-cited articles, 63 were related to medicine. In total, 96% of articles were published in the United States, and 80% were published in the year 2000 or later. Of the top 100 articles, 85 were observational; only 5 were experimental. The sport most represented was soccer, followed by football, baseball, and basketball. Of the top 100 articles, 21 were published in a single journal, the American Journal of Sports Medicine. Ten authors published ≥5 of the top 100 most-cited studies. Conclusion: The majority of top 100 articles were published in the United States after 1999 and primarily focused on medicine-related topics. Soccer was studied by more articles than football, baseball, and basketball. An author’s prestige may have influenced the likelihood of citation. The top 100 most-cited studies provide researchers, medical students, residents, and fellows with a foundational list of the most important and influential academic contributions to the literature on collegiate athletics.